Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that usually presents in the first few years of life [1]. Less than a quarter of cases are familial, following an autosomal dominant pattern [2]. The majority of cases are sporadic mutations that can then be passed down to offspring.

DBA is thought to arise from a disturbance in ribosome formation, coded for by the ribosomal protein S19 (RPS19) gene [3]. It is mainly defined by a hypoplastic, macrocytic anemia that may be accompanied by various congenital abnormalities [4]. The white cell and platelet counts typically remain within, or just below, normal ranges [5].

DBA often presents with severe anemia in infancy or childhood, which may be fatal [6]. Newborns may have a low birth weight, followed by growth retardation. Outward signs of disease are pallor, especially while feeding, and shortness of breath. There is usually no associated organomegaly.

It is estimated that half of the children affected by DBA also exhibit physical abnormalities. The craniofacial features of DBA are the most commonly occurring abnormalities, some of which are hypertelorism, microcephaly, microtia, cleft palate, and a flattened nasal bridge. Pierre-Robin syndrome, congenital glaucoma, and cataracts have also been described.

Musculoskeletal features include short stature, webbed neck, and upper limb deformities such as triphalangeal thumbs, and complete absence of the radius or forearm. Puberty may be delayed, however, the rest of the developmental history is normal. In contrast, intellectual disability is not a part of the syndrome. Other systems that are characteristically disturbed are the urogenital and cardiovascular systems [4]. This results in conditions such as hypospadias, horseshoe kidneys, ventricular septal defect, atrial septal defect, and coarctation of the aorta.

In addition to the above, children with DBA have a higher risk of developing leukemia and various solid tumors, exemplified by acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and osteosarcoma [7].

Less severe, non-classic forms of the disease do occur, characterized by mild anemia (if present), asymptomatic macrocytosis, high HbF (fetal hemoglobin) and isolated physical abnormalities.

The diagnosis of Diamond-Blackfan anemia can be made based on family history, prenatal genetic testing in cases of known mutations, as well as a raised erythrocyte adenosine deaminase (EAD) [8].

Further laboratory tests include:

• Complete blood count: A raised mean cell volume (MCV) may be present, with a normal white cell and platelet count, and a low percentage of reticulocyte count.
• Peripheral blood smear: This may show normochromic, macrocytic red blood cells.
• Bone marrow aspirate: This test is used to confirm the absence of red cell production in the bone marrow (erythroblastopenia). Furthermore, samples are tested for parvovirus B19, which can cause bone marrow suppression.
• Radiological: The skeletal deformities can be easily observed through various radiological means.
• Cardiac and renal function monitoring are also indicated.

Treatment for Diamond-Blackfan Anemia Type 2 primarily focuses on managing anemia and its symptoms. Corticosteroids, such as prednisone, are often the first line of treatment and can stimulate red blood cell production in some patients. Blood transfusions may be necessary for those who do not respond to steroids. In severe cases, a bone marrow transplant may be considered, offering a potential cure by replacing the defective bone marrow with healthy donor cells.

The prognosis for individuals with Diamond-Blackfan Anemia Type 2 varies depending on the severity of the condition and response to treatment. With appropriate management, many patients can lead relatively normal lives. However, there is an increased risk of developing complications such as iron overload from repeated blood transfusions and a higher likelihood of certain cancers. Regular monitoring and follow-up care are essential to address these risks.

Diamond-Blackfan Anemia Type 2 is caused by mutations in the RPS19 gene, which is responsible for producing a component of the ribosome. These mutations disrupt normal ribosome function, leading to impaired red blood cell production. The condition is inherited in an autosomal dominant manner, meaning a single copy of the mutated gene from an affected parent can cause the disorder.

Diamond-Blackfan Anemia is a rare condition, with an estimated incidence of 5 to 7 cases per million live births worldwide. DBA Type 2, associated with RPS19 mutations, accounts for approximately 25% of all DBA cases. The disorder affects both males and females equally and has been reported in various ethnic groups.

The pathophysiology of Diamond-Blackfan Anemia Type 2 involves defective ribosome biogenesis due to mutations in the RPS19 gene. Ribosomes are essential for protein synthesis, and their dysfunction leads to impaired production of red blood cells. This results in anemia and the associated clinical manifestations. The exact mechanisms by which RPS19 mutations lead to the specific features of DBA are still under investigation.

Currently, there are no specific measures to prevent Diamond-Blackfan Anemia Type 2, as it is a genetic disorder. Genetic counseling is recommended for families with a history of the condition to understand the risks and implications of inheritance. Prenatal testing and preimplantation genetic diagnosis may be options for at-risk couples planning a family.

Diamond-Blackfan Anemia Type 2 is a rare genetic disorder characterized by anemia due to impaired red blood cell production. It is caused by mutations in the RPS19 gene and presents with symptoms such as fatigue and pallor, often accompanied by physical abnormalities. Diagnosis involves blood tests and genetic analysis, while treatment focuses on managing anemia through medications, transfusions, or bone marrow transplant. Prognosis varies, and regular monitoring is essential to manage potential complications.

If you or a loved one has been diagnosed with Diamond-Blackfan Anemia Type 2, it's important to understand that this is a rare genetic condition affecting red blood cell production. Symptoms often include tiredness and pale skin, and treatment may involve medications or blood transfusions. While the condition can be challenging, many patients manage well with proper care. Genetic counseling can provide valuable information for families with a history of the disorder.

1. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23(2):261-282.
2. Johns Hopkins University. Diamond-Blackfan Anemia 1, DBA1. Online Mendelian Inheritance in Man (OMIM). https://www.omim.org/entry/105650. Updated March 28, 2017. Accessed September 9, 2017.
3. Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815-3819.
4. Campagnoli MF, Ramenghi U, Armiraglio M, et al. RPS19 mutations in patients with Diamond-Blackfan anemia. Hum Mutat. 2008;29(7):911-920.
5. Gazda HT, Sieff CA. Recent insights into the pathogenesis of Diamond-Blackfan anaemia. Br J Haematol. 2006;135(2):149-157.
6. Ellis SR. Nucleolar stress in Diamond Blackfan anemia pathophysiology. Biochim Biophys Acta. 2014;1842(6):765-768.
7. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150(2):179-188.
8. Clinton C, Gazda HT. Diamond-Blackfan Anemia. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK7047/. Published 25 Jun, 2009. Updated 7 April, 2016. Accessed 18 September, 2017.